AU2022342928A1 - Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody - Google Patents
Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody Download PDFInfo
- Publication number
- AU2022342928A1 AU2022342928A1 AU2022342928A AU2022342928A AU2022342928A1 AU 2022342928 A1 AU2022342928 A1 AU 2022342928A1 AU 2022342928 A AU2022342928 A AU 2022342928A AU 2022342928 A AU2022342928 A AU 2022342928A AU 2022342928 A1 AU2022342928 A1 AU 2022342928A1
- Authority
- AU
- Australia
- Prior art keywords
- igg
- note
- nonenglishqualifier
- qualifiers
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021146504 | 2021-09-08 | ||
| JP2021-146504 | 2021-09-08 | ||
| PCT/JP2022/033713 WO2023038082A1 (ja) | 2021-09-08 | 2022-09-08 | 化合物、化合物の塩、抗体修飾試薬、修飾抗体の製造方法及び修飾抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022342928A1 true AU2022342928A1 (en) | 2024-03-28 |
Family
ID=85506405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022342928A Pending AU2022342928A1 (en) | 2021-09-08 | 2022-09-08 | Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250304617A1 (https=) |
| EP (1) | EP4400509A1 (https=) |
| JP (1) | JPWO2023038082A1 (https=) |
| KR (1) | KR20240052833A (https=) |
| CN (1) | CN117916251A (https=) |
| AU (1) | AU2022342928A1 (https=) |
| CA (1) | CA3231257A1 (https=) |
| TW (1) | TW202328163A (https=) |
| WO (1) | WO2023038082A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026058917A1 (ja) * | 2024-09-10 | 2026-03-19 | 味の素株式会社 | 抗体親和性物質を含む化合物、修飾抗体およびそれらの塩ならびに抗体誘導体または抗体－機能性物質コンジュゲートの製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008054030A1 (fr) | 2006-11-02 | 2008-05-08 | Kagoshima University | Peptide liant l'igg |
| JP5994068B2 (ja) | 2011-08-24 | 2016-09-21 | 国立大学法人 鹿児島大学 | ＩｇＧ結合性ペプチド及びそれによるＩｇＧの検出および精製方法 |
| ES3058443T3 (es) | 2015-05-20 | 2026-03-10 | Univ Kagoshima | Modificación específica de anticuerpo con péptido de unión a IgG |
| DK3470418T3 (da) | 2016-06-13 | 2024-09-30 | Univ Kagoshima | Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid |
| AU2018259856B2 (en) | 2017-04-28 | 2025-05-01 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
| JP7291395B2 (ja) | 2017-06-16 | 2023-06-15 | 国立大学法人 鹿児島大学 | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| TWI886164B (zh) * | 2019-10-24 | 2025-06-11 | 國立大學法人鹿兒島大學 | 1價ccap生成物之製造方法 |
| JP7461180B2 (ja) | 2020-03-16 | 2024-04-03 | 五洋建設株式会社 | プレキャスト部材の鉄筋挿入孔の形成方法、プレキャスト部材の接合方法およびプレキャスト部材の製造方法 |
-
2022
- 2022-09-08 JP JP2023546982A patent/JPWO2023038082A1/ja active Pending
- 2022-09-08 TW TW111134182A patent/TW202328163A/zh unknown
- 2022-09-08 AU AU2022342928A patent/AU2022342928A1/en active Pending
- 2022-09-08 WO PCT/JP2022/033713 patent/WO2023038082A1/ja not_active Ceased
- 2022-09-08 CN CN202280060866.4A patent/CN117916251A/zh active Pending
- 2022-09-08 KR KR1020247011055A patent/KR20240052833A/ko active Pending
- 2022-09-08 US US18/690,185 patent/US20250304617A1/en active Pending
- 2022-09-08 EP EP22867403.2A patent/EP4400509A1/en active Pending
- 2022-09-08 CA CA3231257A patent/CA3231257A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4400509A1 (en) | 2024-07-17 |
| US20250304617A1 (en) | 2025-10-02 |
| JPWO2023038082A1 (https=) | 2023-03-16 |
| WO2023038082A1 (ja) | 2023-03-16 |
| CA3231257A1 (en) | 2023-03-16 |
| CN117916251A (zh) | 2024-04-19 |
| TW202328163A (zh) | 2023-07-16 |
| KR20240052833A (ko) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qu et al. | New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties | |
| ES3058443T3 (es) | Modificación específica de anticuerpo con péptido de unión a IgG | |
| AU2025204808A1 (en) | Binding agents | |
| Rousselle et al. | Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy | |
| AU2024202695A1 (en) | Alpha-v beta-6 integrin ligands and uses thereof | |
| ES2332175T3 (es) | Anticuerpo que tiene una especificidad tipo receptor de celulas t, con una afinidad aun mayor y el uso del mismo en la deteccion y tratamiento del cancer, infecciones viricas y enfermedades autoinmunes. | |
| DK2889624T3 (en) | Reversible covalent bonding of functional molecules | |
| AU2024227071A1 (en) | Polypeptides and uses thereof | |
| KR102529359B1 (ko) | 항-cd71 활성화 가능한 항체 약물 접합체 및 이의 사용 방법 | |
| US20230158167A1 (en) | Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof | |
| AU2024223986A1 (en) | Aggrecan binding immunoglobulins | |
| US10184008B2 (en) | Blood brain barrier transport molecules and uses thereof | |
| US20160003836A1 (en) | Photo or chemolabile conjugates for molecules detection | |
| WO1997046547A1 (en) | β-SHEET NUCLEATING PEPTIDOMIMETICS | |
| AU2022342928A1 (en) | Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody | |
| US12054560B2 (en) | Bifunctional molecules recruiting antibodies and targeting cancer cells | |
| Rocha et al. | Design and biological activity of β-sheet breaker peptide conjugates | |
| KR20170042792A (ko) | 항체 결합성 폴리펩타이드, 항체 결합성 융합 폴리펩타이드 및 흡착 재료 | |
| AU2024208633A1 (en) | Neuroprotective psd-95 polypeptide inhibitor and use thereof | |
| EP0029300A1 (en) | Polypeptides, antisera containing them and methods of their use | |
| Péan et al. | Synthesis and characterization of peptidyl-cyclodextrins dedicated to drug targeting | |
| CA3172265A1 (en) | Antibodies against tdp-43 and methods of using the same | |
| HK40109611A (zh) | 化合物、化合物的盐、抗体修饰试剂、修饰抗体的制造方法及修饰抗体 | |
| US20250154202A1 (en) | Cyclic epitope tags | |
| CN120457144A (zh) | 产生作为α7烟碱乙酰胆碱受体的沉默和正变构调节剂的抗体 |